Ignite Creation Date:
2024-05-06 @ 8:26 AM
Last Modification Date:
2024-10-26 @ 12:00 PM
Study NCT ID:
NCT02732119
Status:
COMPLETED
Last Update Posted:
2021-05-05
First Post:
2016-04-04
Brief Title:
Study of Ribociclib With Everolimus Exemestane in HR HER2- Locally AdvancedMetastatic Breast Cancer Post Progression on CDK 46 Inhibitor
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Breast Cancer |
Keywords:
| Name | View |
|---|---|
| adult | View |
| HR-positive | View |
| HER2-negative | View |
| Advanced breast cancer | View |
| LEE011 | View |
| ribociclib | View |
| everolimus | View |
| Afinitor | View |
| exemestane | View |
| Aromasin | View |
| CDK | View |
| CDK4 | View |
| CDK6 | View |
| CDK46 | View |
| CDK46 inhibitor | View |
| Phase I | View |
| Phase II | View |
| ER-positive | View |
| PR-positive | View |
| Postmenopausal | View |